A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Phesgo® Biosimilar HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 1
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Qi Jin
- Telefonní číslo: 86 159 5516 0489
- E-mail: Qi_jin@henlius.com
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Voluntary participation in the clinical study and signed the Informed Consent Form (ICF).
- Male or female aged ≥ 18 years old at the time of signing the ICF;
- Histologically confirmed invasive breast cancer, stage II-IIIC, Human Epidermal Growth Factor Receptor 2 (HER2) positive confirmed by central laboratory.
- Participants agree to undergo surgery while meeting the criteria for surgery after neoadjuvant therapy.
- Left ventricular ejection fraction (LVEF) at baseline ≥ 55%.
- An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.
- Adequate major organ functions.
- Women with child-bearing potential have a negative result of serum pregnancy test at screening period (within 7 days prior to the first dose) or if they are infertile, non- lactating, reproduction-age men and women following highly effective contraceptive measures until 7 months after last dose.
Exclusion Criteria:
- Stage IV breast cancer, bilateral breast cancer, or multicentric breast cancer.
- History of other malignancy within 5 years.
- Prior systemic therapy for breast cancer treatment or radiotherapy.
- Patients with a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) who have received systemic therapy or radiotherapy to the ipsilateral breast.
- Patients who have undergone excision biopsy of the primary tumor and/or axillary lymph nodes or lymph node dissection.
- Have severe heart disease or medical conditions.
- Participants with viral hepatitis or those with autoimmune hepatitis, sclerosing cholangitis, or liver cirrhosis.
- Human Immunodeficiency Virus (HIV) infection, HIV antibody positive.
- Daily use of corticosteroid treatment is required.
- Sensitivity to any study medications or any of its ingredients or excipients.
- Participants who underwent any major surgery within 28 days prior to the first dose. Or participants who have received local radiotherapy, radiofrequency ablation, or interventional therapy within 2 weeks prior to the first dose.
- Received another interventional clinical trial therapy within 4 weeks prior to enrollment in the study, or intentionally participated in another interventional clinical trial during the entire study period.
- Severe, uncontrolled systemic diseases that may currently interfere with the therapeutic plan.
- Any other conditions which are inappropriate for the study in the opinion of the investigator.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: HLX319
The regimen in the experimental group is HLX319 in combination with docetaxel and carboplatin.
|
HLX319 is a biosimilar of pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
|
|
Aktivní komparátor: EU-Phesgo®
The regimen in the control group is EU-Phesgo® in combination with docetaxel and carboplatin.
|
EU-Phesgo® is an original marketed drug product, with the generic name pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Peak concentration (Cmax)
Časové okno: up to 180 days
|
Peak concentration after a single drug administration in Cycle 1.
|
up to 180 days
|
|
Area under the serum drug concentration-time curve from 0 to 21 days (AUC0-21d)
Časové okno: up to 180 days
|
Area under the serum drug concentration-time curve from 0 to 21 days after a single drug administration in Cycle 1.
|
up to 180 days
|
|
Steady-state peak concentration (Cmax,ss)
Časové okno: up to 180 days
|
The steady-state peak concentration after multiple doses administration in Cycle 4.
|
up to 180 days
|
|
Steady-state area under the serum drug concentration-time curve within a dosing interval (AUCss)
Časové okno: up to 180 days
|
Steady-state area under the serum drug concentration-time curve within a dosing interval after multiple doses administration in Cycle 4.
|
up to 180 days
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Trough concentration (Ctrough)
Časové okno: up to 180 days
|
Trough concentration after a single dose administration
|
up to 180 days
|
|
Area under the serum drug concentration-time curve from time 0 to infinity (AUC0-inf)
Časové okno: up to 180 days
|
Area under the serum drug concentration-time curve from time 0 to infinity after a single dose administration
|
up to 180 days
|
|
Percentage of extrapolated area in the total AUC (%AUCex)
Časové okno: up to 180 days
|
Percentage of extrapolated area in the total AUC after a single dose administration
|
up to 180 days
|
|
Time to peak concentration (Tmax)
Časové okno: up to 180 days
|
time to peak concentration after a single dose administration
|
up to 180 days
|
|
Elimination half-life (T1/2)
Časové okno: up to 180 days
|
elimination half-life after a single dose administration
|
up to 180 days
|
|
Total clearance (CL/F)
Časové okno: up to 180 days
|
total clearance after a single dose administration
|
up to 180 days
|
|
Terminal phase distribution volume (Vz/F)
Časové okno: up to 180 days
|
terminal phase distribution volume after a single dose administration
|
up to 180 days
|
|
Mean residence time (MRT)
Časové okno: up to 180 days
|
mean residence time after a single dose administration
|
up to 180 days
|
|
Steady-state trough concentration (Ctrough,ss)
Časové okno: up to 180 days
|
steady-state trough concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Average steady-state concentration (Caverage,ss)
Časové okno: up to 180 days
|
average steady-state concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state time to peak concentration (Tmax,ss)
Časové okno: up to 180 days
|
steady-state time to peak concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Elimination half-life (T1/2,ss)
Časové okno: up to 180 days
|
elimination half-life after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state volume of distribution (Vss/F)
Časové okno: up to 180 days
|
steady-state volume of distribution after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state total clearance (CLss/F)
Časové okno: up to 180 days
|
steady-state total clearance after multiple doses administration in Cycle 4
|
up to 180 days
|
|
accumulation ratio based on Cmax (RCmax)
Časové okno: up to 180 days
|
accumulation ratio based on Cmax after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Accumulation ratio based on AUC (RAUC)
Časové okno: up to 180 days
|
accumulation ratio based on AUC after multiple doses administration in Cycle 4
|
up to 180 days
|
|
The total pathological complete response (tpCR) rate assessed by the investigator
Časové okno: up to 180 days
|
up to 180 days
|
|
|
Breast pathologic complete response (bpCR) rate assessed by the investigator
Časové okno: up to 180 days
|
up to 180 days
|
|
|
Objective response rate (ORR) assessed by the investigator
Časové okno: up to 180 days
|
according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria
|
up to 180 days
|
|
Incidence and severity of adverse events (AEs)
Časové okno: up to 180 days
|
severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 6.0
|
up to 180 days
|
|
Number of participants with abnormal vital signs
Časové okno: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal physical examination findings
Časové okno: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal Laboratory tests results
Časové okno: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal 12-lead ECG readings
Časové okno: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Positivity rates of anti-drug antibodies (ADA)
Časové okno: up to 180 days
|
up to 180 days
|
|
|
Positivity rates of neutralizing antibodies (NAb)
Časové okno: up to 180 days
|
up to 180 days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- HLX319-BC001
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .